INSTEAD Trial: INvestigation of STEnt Grafts in Patients With Type B Aortic Dissection (INSTEAD)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00525356|
Recruitment Status : Completed
First Posted : September 5, 2007
Last Update Posted : October 29, 2015
|Condition or disease||Intervention/treatment||Phase|
|Aortic Diseases||Device: Medtronic Talent Stent-Graft-System||Phase 3|
Patients older than 18 years with type B aortic dissection as diagnosed by computed tomography or magnetic resonance angiography are randomized to either a thoracic aortic endoprosthesis and antihypertensive treatment, called "stent grafting," or a tailored antihypertensive treatment, called "medical treatment."
Only patients in a clinically stable condition and without spontaneous thrombosis of the false lumen after 14 days of the index dissection are considered eligible for study inclusion.
Primary outcome measure is all-cause mortality. Secondary outcome variables include conversion to stent and/or surgery, induced thrombosis of the false lumen, cardiovascular morbidity, aortic expansion (>5 mm/y of maximum diameter including true and false lumina), quality of life, and length of intensive care unit and hospital stay. The study design calls for 136 patients to be randomized and monitored for 24 months.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||136 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||INvestigation of STEnt Grafts in Patients With Type B Aortic Dissection|
|Study Start Date :||February 2002|
|Study Completion Date :||September 2007|
Active Comparator: 1
Anti-hypertensive medical treatment
Device: Medtronic Talent Stent-Graft-System
Other Name: Endograft
- all-cause mortality [ Time Frame: 1 year ]
- thrombosis of the false lumen, cardiovascular morbidity, degree of aortic expansion, length of intensive care and hospital stay, and quantitative assessment of single or combination antihypertensive drug therapy. [ Time Frame: 5 years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00525356
|Medtronic Bakken Research Center|
|Maastricht, Netherlands, 6229 GW|
|Principal Investigator:||C A Nienaber, MD, FESC, FACC||Division of Cardiology and Internal Medicine Department, Rostock University, Germany.|